X0306 4 2021-12-17 0 0001340652 ChemoCentryx, Inc. CCXI 0001324991 Tyree James L C/O CHEMOCENTRYX, INC. 835 INDUSTRIAL ROAD, SUITE 600 SAN CARLOS CA 94070 1 0 0 0 Common Stock 2021-12-17 4 M 0 25000 12.62 A 40275 D Common Stock 2021-12-17 4 M 0 12500 14.42 A 52775 D Common Stock 2021-12-17 4 S 0 2800 33.52 D 49975 D Common Stock 2021-12-17 4 S 0 16634 34.7417 D 33341 D Common Stock 2021-12-17 4 S 0 18066 35.504 D 15275 D Stock Option (right to buy) 12.62 2021-12-17 4 M 0 25000 D 2022-06-05 Common Stock 25000 0 D Stock Option (right to buy) 14.42 2021-12-17 4 M 0 12500 D 2022-06-22 Common Stock 12500 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $33.14 to $34.09 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $34.15 to $35.14 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $35.15 to $35.90 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. As of December 17, 2021, and prior to this transaction, the exercised options were fully vested. Not applicable. /s/ Susan M. Kanaya, as Attorney-in-Fact 2021-12-21